Trading Signals: MRNA Stock Price Prediction and Forecast (Fri. Dec. 7, 2018 - Wed. Mar. 3, 2021)(Moderna, Inc)
| MRNA latest price $71.9500 (4.56%) ($69.0500 - $72.0200) on Mon. Oct. 5, 2020. | |
| | Trend Analysis and Forecast | | | Trend Pattern | Growing Uptrend | Trend Narrative | Uptrend | Average Daily Price Swing | $5.1 (7.65% one month average) | Average Daily Percentage Swing | 4.93% (three month average) | Weekly Trend Force | 0.5% (StdDev 4.93%) | Daily Moving Force | 0.5% | Correction Force | Weak (0%) | Trend | 0.36% | Trend Strength | 4.1% | RSI | 63 | Momentum | 1.6 | Latest Price | $71.9500(4.56%) | Forecasted Low Price | 71.09(-1.2%) | Forecasted High Price | 73.53(2.2%) | Direction of Next Movement | Range(0.7%) | % Change Needed to Confirm Correction | 4.7% (68.73) | % Change Needed for Trend Reversal | 6.2% | Hourly Trend | 0.8% [$69.92(0.58), $70.39(0.05)] | Stocks Behave Similarly | Similar Stock List | Complacency | 4 | Intraday Reversal Probability | N/A. | Daily Trend | MRNA advances 0.4% a day on average for past five trading days. | Weekly Trend | MRNA advances 1.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support MRNA advance at 0.8% a week (40% probability) IPO(46%) IBB(45%) XBI(41%) ARKK(33%) ARKG(31%) | Factors Impacting MRNA price | MRNA will decline at least -1.1% in a week (8% probabilities). VIXM(-13%) VXX(-6%) INDA(-6%) TBT(-5%) URA(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | Trading Plan | Not Available | | | Valuation to SPY | -0.6 | | | Relative Volatility | 1.8 (options are extremely expensive) | | | Market Trend Strength | 0.2% (StdDev 4.93%) | Hourly BBV | 1.7 () | Intraday Trend | 3.3% | | | |
|
Next Day Open Price | $72.01(0.08%) | Inflection Point | Yes | Support Level | $66.65 | 5 Day Moving Average | $70.41(2.19%) | 10 Day Moving Average | $69.39(3.69%) | 20 Day Moving Average | $66.65(7.95%) | To recent high | -24.1% | To recent low | 32.4% | Market Cap | $28.296b | | Option Sentiment | | | | Earning Release Date | Wed. Mar. 10, 2021 | Analyst One Year Target Price | $92.29 ($41.00 - $134.00) 14 analysts (last updated on Wed. Sep. 30, 2020) | % to Average Target Price | 28.27% | % to Low Target Price | -43.02% | % to High Target Price | 86.24% | | |
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
July 7, 2020 MRNA, which has developed a vaccine candidate mRNA-1273, is in its phase 2 clinical trials. The mRNA is a molecule that genetically encodes a set of instructions, based on which cells make proteins and send them to various parts of the body. |